What to look out for at the AACR meeting
This article was originally published in Scrip
Executive Summary
This year's American Association of Cancer Research (AACR) meeting in Philadelphia (18-22 April) looks set to reveal data in several hot areas of research such as immune-oncology, including checkpoint inhibitors and PD-1/PD-L1-acting products.
You may also be interested in...
Another Failure For Biohaven’s Troriluzole
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.
Need a specific report? 1000+ reports available
Buy Reports